glp-1 drugs and thyroid cancer Increased screening may lead to higher risk after initiation Glucagon-like peptide-1 receptor agonists &

Another review looked at how well different GLP-1 receptor agonists worked when added to metformin in people with type 2 diabetes

Medical Research Archives, [online] 12(10)

This approach is more precise than relying on the report odds ratio, particularly in situations with limited cases [30]

Clinical evidence: key trials and outcomes The kidney-protective potential of SGLT2 inhibitors was first identified in cardiovascular outcome trials, including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose (EMPA-REG OUTCOME) [36], Canagliflozin Cardiovascular Assessment Study (CANVAS) [37], and Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARETIMI 58) [38]

In healthy people, postprandial GIP levels are approximately 4-fold higher than GLP-1 levels